Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H6O2 |
Molecular Weight | 158.1534 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1C=CC(=O)C2=C1C=CC=C2
InChI
InChIKey=FRASJONUBLZVQX-UHFFFAOYSA-N
InChI=1S/C10H6O2/c11-9-5-6-10(12)8-4-2-1-3-7(8)9/h1-6H
Molecular Formula | C10H6O2 |
Molecular Weight | 158.1534 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1806 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22218491 |
10.8 µM [IC50] | ||
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22071524 |
1.5 µM [Ki] | ||
Target ID: CHEMBL1951 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22071524 |
7.7 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Molecular modeling and 3D-QSAR studies in 2-aziridinyl-and 2,3-bis(aziridinyl)-1,4-naphthoquinonyl sulfonate and acylate derivatives as potential antimalarial agents. | 2001 |
|
[Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use]. | 2001 |
|
Bromination studies of the 2,3-dimethylnaphthazarin core allowing easy access to naphthazarin derivatives. | 2001 Aug 10 |
|
A new naphthoquinone from Pyrola japonica. | 2001 Dec |
|
Association of quinone-induced platelet anti-aggregation with cytotoxicity. | 2001 Jul |
|
Quinone isomers of the WS-5995 antibiotics: synthetic antitumor agents that inhibit macromolecule synthesis, block nucleoside transport, induce DNA fragmentation, and decrease the growth and viability of L1210 leukemic cells more effectively than ellagic acid and genistein in vitro. | 2001 Jun |
|
Recruitment of a foreign quinone into the A1 site of photosystem I. In vivo replacement of plastoquinone-9 by media-supplemented naphthoquinones in phylloquinone biosynthetic pathway mutants of Synechocystis sp. PCC 6803. | 2001 Oct 26 |
|
Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol. | 2001 Sep |
|
[Studies on the inhibition of polyhydroxylated aromatic compounds against HIV-1 integrase]. | 2002 Apr |
|
A new naphthoquinone from Polygonum aviculare. | 2002 Apr |
|
Lindbladione and related naphthoquinone pigments from a myxomycete Lindbladia tubulina. | 2002 Aug |
|
Chloroquinocin, a novel chlorinated naphthoquinone antibiotic from Streptomyces sp., LL-A9227. | 2002 Dec |
|
2-(Pyrrolidin-1-yl)-1,4-naphthoquinone and 2-phenylsulfanyl-3-(pyrrolidin-1-yl)-1,4-naphthoquinone. | 2002 Dec |
|
Placement and characterization of pairs of luminescent molecules in spatially separated regions of nanostructured thin films. | 2002 Dec 4 |
|
Geranyl diphosphate:4-hydroxybenzoate geranyltransferase from Lithospermum erythrorhizon. Cloning and characterization of a ket enzyme in shikonin biosynthesis. | 2002 Feb 22 |
|
Solubilization of a naphthoquinone derivative by hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and polyvinylpyrrolidone (PVP-K30). The influence of PVP-K30 and pH on solubilizing effect of HP-beta-CD. | 2002 Jan-Feb |
|
[Respiratory activity and naphthoquinone synthesis in the fungus Fusarium decemcellulare exposed to oxidative stress]. | 2002 Mar-Apr |
|
Synthesis of 2-alkoxy 1,4-naphthoquinone derivatives as antiplatelet, antiinflammatory, and antiallergic agents. | 2002 May |
|
Three new naphthoquinone derivatives from Diospyros maritima Blume. | 2002 May |
|
Cyclooxygenase-2 inhibitory 1,4-naphthoquinones from Impatiens balsamina L. | 2002 May |
|
Why do co-solvents enhance the solubility of solutes in supercritical fluids? New evidence and opinion. | 2002 Nov 15 |
|
Synthesis of monocarbenepalladium(0) complexes and their catalytic behavior in cross-coupling reactions of aryldiazonium salts. | 2002 Sep 2 |
|
Feasibility of atmospheric pressure desorption/ionization on silicon mass spectrometry in analysis of drugs. | 2003 |
|
Mechanisms for naphthalene removal during electrolytic aeration. | 2003 Feb |
|
Synthesis and biological evaluation of some new substituted naphthoquinones. | 2003 Jun |
|
Discriminating redox cycling and arylation pathways of reactive chemical toxicity in trout hepatocytes. | 2003 Mar |
|
Total syntheses of furaquinocin A, B, and E. | 2003 Oct 29 |
|
Cytotoxicity and DNA topoisomerase inhibitory activity of benz[f]indole-4,9-dione analogs. | 2003 Sep |
|
A new naphthoquinone from Ceiba pentandra. | 2003 Sep |
|
Alternative quinone substrates and inhibitors of human electron-transfer flavoprotein-ubiquinone oxidoreductase. | 2004 Mar 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Rat LD50 (oral) 190mg/kg
Mouse LD50 (intraperitoneal) 5500µg/kg
Guinea Pig LD50 (oral) 400mg/kg
Rat LD50 (oral) 190mg/kg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26666298
1,4-naphthoquinone exhibited cytotoxic
activity against HepG2 cell line with the IC50 value of 13.75±0.74 uM. It exhibited very potent ABTS+ cation radical scavenging activity with IC50 value of 7.97 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:02:36 GMT 2023
by
admin
on
Fri Dec 15 19:02:36 GMT 2023
|
Record UNII |
RBF5ZU7R7K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID5040704
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | |||
|
8530
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | |||
|
2037
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | |||
|
9583
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | |||
|
RBF5ZU7R7K
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | |||
|
204-977-6
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | |||
|
RBF5ZU7R7K
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | |||
|
27418
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | |||
|
1602556
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | RxNorm | ||
|
m7750
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
1,4-NAPHTHOQUINONE
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY | |||
|
130-15-4
Created by
admin on Fri Dec 15 19:02:37 GMT 2023 , Edited by admin on Fri Dec 15 19:02:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
IN VITRO
|